Dongli Zhang, Jie Li, Yaqi Liang, Tao Li, Ming Ji, Xinmin Liu, Wenxin Li, Pengxiao Chen, Jiamin Zhang, Zhengduo Yang, Lulu Wang* and He Chen*,
{"title":"细胞外hsp90促进双功能小分子降解细胞外和膜蛋白。","authors":"Dongli Zhang, Jie Li, Yaqi Liang, Tao Li, Ming Ji, Xinmin Liu, Wenxin Li, Pengxiao Chen, Jiamin Zhang, Zhengduo Yang, Lulu Wang* and He Chen*, ","doi":"10.1021/acs.jmedchem.5c00379","DOIUrl":null,"url":null,"abstract":"<p >Lysosome-targeting chimeras represent a promising strategy for degrading extracellular and membrane proteins via the lysosomal pathway, but the available receptor options remain limited. Herein, we report a novel strategy utilizing extracellular heat shock protein 90 (eHSP90) to facilitate lysosomal degradation of target proteins through bifunctional small molecules, termed extracellular heat shock protein 90-targeting chimeras (eHSPTACs). By connecting an HSP90 ligand to a target protein ligand, eHSPTACs effectively induced the internalization and subsequent lysosomal degradation of extracellular Alexa Fluor 488-labeled α-DNP antibody and membrane programmed cell death-ligand 1 (PD-L1). Notably, <b>dPDL1-4</b> selectively degraded membrane PD-L1 in tumor cells over normal cells, leveraging the elevated expression of eHSP90 in cancer cells. Moreover, <b>dPDL1-4</b> demonstrated robust in vivo degradation of membrane PD-L1 and significant tumor growth suppression in the B16F10 syngeneic mouse model. Overall, eHSPTACs offer a general platform for tumor-selective degradation of extracellular and membrane proteins, providing a new therapeutic avenue.</p>","PeriodicalId":46,"journal":{"name":"Journal of Medicinal Chemistry","volume":"68 12","pages":"12641–12657"},"PeriodicalIF":6.8000,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Extracellular HSP90-Facilitated Degradation of Extracellular and Membrane Proteins by Bifunctional Small Molecules\",\"authors\":\"Dongli Zhang, Jie Li, Yaqi Liang, Tao Li, Ming Ji, Xinmin Liu, Wenxin Li, Pengxiao Chen, Jiamin Zhang, Zhengduo Yang, Lulu Wang* and He Chen*, \",\"doi\":\"10.1021/acs.jmedchem.5c00379\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p >Lysosome-targeting chimeras represent a promising strategy for degrading extracellular and membrane proteins via the lysosomal pathway, but the available receptor options remain limited. Herein, we report a novel strategy utilizing extracellular heat shock protein 90 (eHSP90) to facilitate lysosomal degradation of target proteins through bifunctional small molecules, termed extracellular heat shock protein 90-targeting chimeras (eHSPTACs). By connecting an HSP90 ligand to a target protein ligand, eHSPTACs effectively induced the internalization and subsequent lysosomal degradation of extracellular Alexa Fluor 488-labeled α-DNP antibody and membrane programmed cell death-ligand 1 (PD-L1). Notably, <b>dPDL1-4</b> selectively degraded membrane PD-L1 in tumor cells over normal cells, leveraging the elevated expression of eHSP90 in cancer cells. Moreover, <b>dPDL1-4</b> demonstrated robust in vivo degradation of membrane PD-L1 and significant tumor growth suppression in the B16F10 syngeneic mouse model. Overall, eHSPTACs offer a general platform for tumor-selective degradation of extracellular and membrane proteins, providing a new therapeutic avenue.</p>\",\"PeriodicalId\":46,\"journal\":{\"name\":\"Journal of Medicinal Chemistry\",\"volume\":\"68 12\",\"pages\":\"12641–12657\"},\"PeriodicalIF\":6.8000,\"publicationDate\":\"2025-06-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Medicinal Chemistry\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://pubs.acs.org/doi/10.1021/acs.jmedchem.5c00379\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medicinal Chemistry","FirstCategoryId":"3","ListUrlMain":"https://pubs.acs.org/doi/10.1021/acs.jmedchem.5c00379","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
Extracellular HSP90-Facilitated Degradation of Extracellular and Membrane Proteins by Bifunctional Small Molecules
Lysosome-targeting chimeras represent a promising strategy for degrading extracellular and membrane proteins via the lysosomal pathway, but the available receptor options remain limited. Herein, we report a novel strategy utilizing extracellular heat shock protein 90 (eHSP90) to facilitate lysosomal degradation of target proteins through bifunctional small molecules, termed extracellular heat shock protein 90-targeting chimeras (eHSPTACs). By connecting an HSP90 ligand to a target protein ligand, eHSPTACs effectively induced the internalization and subsequent lysosomal degradation of extracellular Alexa Fluor 488-labeled α-DNP antibody and membrane programmed cell death-ligand 1 (PD-L1). Notably, dPDL1-4 selectively degraded membrane PD-L1 in tumor cells over normal cells, leveraging the elevated expression of eHSP90 in cancer cells. Moreover, dPDL1-4 demonstrated robust in vivo degradation of membrane PD-L1 and significant tumor growth suppression in the B16F10 syngeneic mouse model. Overall, eHSPTACs offer a general platform for tumor-selective degradation of extracellular and membrane proteins, providing a new therapeutic avenue.
期刊介绍:
The Journal of Medicinal Chemistry is a prestigious biweekly peer-reviewed publication that focuses on the multifaceted field of medicinal chemistry. Since its inception in 1959 as the Journal of Medicinal and Pharmaceutical Chemistry, it has evolved to become a cornerstone in the dissemination of research findings related to the design, synthesis, and development of therapeutic agents.
The Journal of Medicinal Chemistry is recognized for its significant impact in the scientific community, as evidenced by its 2022 impact factor of 7.3. This metric reflects the journal's influence and the importance of its content in shaping the future of drug discovery and development. The journal serves as a vital resource for chemists, pharmacologists, and other researchers interested in the molecular mechanisms of drug action and the optimization of therapeutic compounds.